Remdesivir didn't reduce coronavirus mortality: WHO study

A clinical trial reportedly found that treatment with remdesivir had no impact on survival in patients with the coronavirus, according to an unpublished study viewed by the FT.

Remdesivir, an antiviral, has received emergency use authorization in the US and other countries based on clinical-trial data that showed it can reduce recovery times in severely ill COVID-19 patients. It has not been proven to reduce death in COVID-19 patients. The trial, which is being conducted by the World Health Organization, found that four drugs - remdesivir, hydroxychloroquine, the HIV combination of lopinavir and ritonavir and interferon - did not produce different mortality rates or reduce the need for ventilation among roughly 11,000 hospitalized patients from 30 countries.

Remdesivir was one of the drugs recently used to treat US President Donald Trump's coronavirus infection.

More on this subject: Coronavirus

Similar articles